LifeShield Medical Files IPO Prospectus: Pioneering Innovation in Global Life Support Technologies Led by Co-Founder Dr. Tim Kaufmann

Many times, the unveiling of devices developed with the assistance of Dr. Tim Kaufmann and his team has drawn significant attention within the industry. Now, as the team steps into the spotlight, their innovative devices are progressively moving into animal testing and human clinical trials, empowering China's life support sector.

Openness, innovation, and mission-driven are the most prominent labels on Dr. Tim Kaufmann. The LifeShield he leads shares the same colors.This internationalized Chinese company, following the completion of a multi-hundred-million-dollar financing round in 2022, has continued to deepen its expertise in China's life support field. It has completed the development of innovative products such as pVAD (percutaneous Ventricular Assist Device), ECMO systems, and ECCO2R (Extracorporeal Carbon Dioxide Removal System). Moreover, the ECMO system is currently entering the human clinical trial phase.。

The story begins with the academic journey of a science and engineering prodigy.

According to Dr. Tim Kaufmann, during his studies in physics at RWTH Aachen University in Germany and the Norwegian University of Science and Technology, he developed an interest in device development. As a result, he chose to research the simulation and development of trileaflet mechanical heart valves for his graduation thesis. Later, while pursuing his Ph.D. in Medical Engineering at RWTH Aachen University, Dr. Tim Kaufmann focused on developing next-generation computer simulation technologies for disease research and medical device development. During his research, he received guidance from Professor Ulrich Steinseifer, head of the Institute for Cardiovascular Engineering at RWTH Aachen University, and also gained a "comrade-in-arms" for his subsequent entrepreneurial journey.

In the scientific research community, Dr. Tim Kaufmann has had a smooth journey, becomingThe Youngest Full Professor at RWTH Aachen University. During the process of scientific research and innovation, he observed the service needs in the development of medical devices: "Some startups have great ideas but lack a research and development department; some large enterprises need to quickly push for product iteration and upgrades." Therefore, Dr. Tim Kaufmann resolutely decided to step out of his comfort zone and enter the industry.

In 2011, Dr. Tim Kaufmann and his mentor Professor Ulrich Steinseifer co-founded enmodes GmbH in Aachen, Germany, focusing on providing development services for medical devices and instruments.Over the past decade, enmodes has assisted medical device companies in more than 20 countries with the development of over 50 cardiovascular devices. Some of these devices have successfully entered the market and achieved leading positions.

Based on this, the enmodes team has accumulated extensive experience in core theoretical foundations such as computer simulation and flow field design; in key technologies like structural design, impeller design, and hemocompatibility; and in the industrialization of devices such as blood pumps and oxygenators. They have mastered the entire process for these highly complex devices from concept, research, and development to clinical trials, and are globally leading in these fields. Meanwhile, the company’s resource network is gradually expanding, forming close collaborations with upstream and downstream enterprises as well as globally leading clinicians.

After successfully aiding the market launch of several innovative devices, Dr. Tim Kaufmann has decided to take the next step – to independently develop devices in China. Only by accumulating strength can one achieve breakthroughs; his original intention is to...Develop more high-quality medical devices to benefit patients in China and even globally.。

Dr. Tim Kaufmann mentioned: "The development potential of the Chinese market is enormous, with infrastructure construction and clinical doctor training being strengthened. The demand for medical device products from patients is also upgrading. We have the ability and responsibility to provide internationally top-tier medical device products to Chinese patients. We excel at this, and it is the right thing to do."

In 2018, Lifeshield Medical was established in the Science and Technology City of Suzhou New District. In 2020, Sun Xiaolu's team from Proxima Ventures had a keen eye and selected the enmodes GmbH team from numerous groups researching left ventricular assist devices and ECMO blood pumps. They also invited former senior Medtronic executive Chen Zulin to serve as CEO, starting the development journey of Lifeshield Medical from scratch.

Lifeshield Medical CEO Chen Zulin has over 20 years of experience in several well-known multinational medical device companies, with extensive expertise in strategic development, market access, business expansion, and team management in the cardiovascular field. He quickly built a local team in China, covering talents from various fields such as medical device R&D, production, quality control, and regulatory affairs. Based on its core technology in the blood pump assistance field, Lifeshield Medical has started a platform-based layout in the life support market.

In 2022, Lifeshield Medical was established. PulmoShield Medical and Germany's enmodes GmbH became two wholly-owned subsidiaries under Lifeshield. Enmodes is positioned as the global R&D center and is responsible for the commercialization of products in the EU market; PulmoShield Medical focuses on collaborative R&D, global production, and commercialization in the Asia-Pacific region.

Starting from one's strengths and finding the clinical needs is Dr. Tim Kaufmann's R&D philosophy. Based on the current uneven distribution of medical and patient resources, he focuses on the field of life support where he has advantages.LifeShield chooses to adopt a "full-platform layout," focusing on the development of highly efficient, safe, and cost-effective products such as pVAD, ECCO2R, and ECMO, and developing comprehensive solutions centered around these products.。

For a startup, a "full-platform" layout presents its own challenges, but LifeShield Medical is not a pure startup. The company has already established a core technology platform and an innovative device development pathway. During the device development process, computer simulation technology is used to model scenarios and treatment situations, allowing for rapid adjustments to product design based on feedback. This greatly enhances development efficiency while also reducing production costs.

As China's aging population intensifies, the prevalence of heart failure continues to rise, with over 10 million heart failure patients in China, yet there remains a lack of effective clinical treatment options. According to Professor Dr. Tim Kaufmann,In China, 1.3 million patients with coronary heart disease undergo PCI surgery every year, of which 30% (nearly 400,000) high-risk patients require intraoperative protection. Additionally, nearly 350,000 patients with cardiogenic shock die each year in China due to lack of timely treatment or effective therapies.。

Impella is the world's only FDA-approved interventional cardiac catheter pump for high-risk PCI or cardiogenic shock patients with severe coronary artery disease. According to data from Abiomed's official website, more than 250,000 patients globally have successfully been treated with Impella, and the safety and efficacy of pVAD therapy have been widely validated. However, this innovative technology and related products have not yet been introduced into China, leaving the domestic market completely untapped.

In the clinical demand for pVAD to provide circulatory support to patients, medium-flow products have a wider range of clinical applications compared to high-flow and low-flow products. Impella series products, which are suitable for high-risk PCI/cardiac shock indications, account for over 80% of sales.LifeShield focuses on the 3L flow market with the widest application and largest scale, while also covering other markets.。

In Dr. Tim Kaufmann's view, pVAD is an extremely complex and sophisticated system. Its development barriers do not lie in a single technology or core component but rather in the need to design and optimize each component while integrating multiple components into a cohesive system. Ensuring the overall functionality of the system involves optimizing multiple processes, including design, manufacturing, and production techniques.

In terms of design, pVAD can be divided into two technical routes: in-body motor and out-of-body motor. Currently, under the out-of-body motor technical route, there is no mature commercialized product available. Moreover, pVADs adopting this design have encountered some issues in clinical applications. The longer flexible bearings in out-of-body motors may pose a risk of fracture, and the design is significantly affected by external factors, carrying higher risks of hemolysis and tissue damage.

In-body motor design remains the mainstream, with Abiomed's classic Impella system adopting this approach, offering advantages such as high transmission efficiency and lower hemolysis risk. However, the miniaturized motor design presents high barriers, as the motor is placed inside the body, requiring smaller size and higher power.LifeShield's pVAD product adopts a built-in motor design, breaking through the patent barriers of imported giants with an innovative "non-perfusion" sealing design to achieve independent innovation.

At the same time, the pVAD needs to rotate tens of thousands of times per minute, a process that can damage human red blood cells and lead to complications such as hemolysis, which is also a pressing issue in clinical practice. Starting from clinical needs,LifeShield optimized the flow field design of the pVAD product, improved the operational efficiency and hemocompatibility of the interventional pump, and has proven in previous animal experiments that there is basically no occurrence of hemolysis.。

Moreover, LifeShield optimizes the overall design of components and pVAD products.Effectively reduce the size of pVAD products, making them operable in catheterization labs and operating rooms, and greatly enhance clinical operational convenience and safety.The company has also optimized the product's manufacturing process, making it easier to "produce" while further reducing production costs. This also means providing more "accessible" therapies and products in China, allowing more patients to benefit from this innovative technology and product, which is conducive to improving the accessibility of pVAD technology.

Dr. Tim Kaufmann mentioned that, with technological upgrades, pVAD will also expand its applications in more clinical fields, with products developing towards being safer, more efficient, and cost-effective. These are precisely the characteristics of LifeShield's products, whose core technological innovations and advantages in industrial chain upgrades will become increasingly prominent.

Beyond cardiovascular diseases, respiratory system diseases are also a key focus for Dr. Tim Kaufmann's team. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and one of the four major chronic diseases in China. There are 100 million COPD patients in China, with a heavy disease burden and a lack of effective treatment options. As COPD progresses, patients experience breathing difficulties, leading to carbon dioxide retention, which affects normal ventilation function. Therefore,A key aspect of COPD treatment is the removal of carbon dioxide from the patient's blood to protect their lungs from further damage.。

In clinical practice, doctors use ventilators to help COPD patients expel carbon dioxide. However, these COPD patients often have inflammatory airways, and continuous application of high pressure may cause further damage. Moreover, while ventilators can provide oxygen, they struggle to remove carbon dioxide and might even harm the lungs further. In recent years, ECCO2R (artificial lung), designed for ECMO systems, has been used in treatment. Although technically capable of removing carbon dioxide, it lacks specificity in system design and vascular pathways, potentially leading to complications like blood clots.

Dr. Tim Kaufmann mentioned: "I like to compare ECMO and ECCO2R to cars. The core components of sports cars and vans are similar, such as wheels and motors, but they are designed for different purposes. Sometimes you need a sports car, sometimes you need a van; one is not better than the other. The main goal for patients with COPD is to remove carbon dioxide from the blood—they need a more targeted and effective ECCO2R system."

ECCO2R can help COPD patients breathe independently, avoid invasive intubation, and assist in the extubation of patients on mechanical ventilation. However, traditional ECCO2R systems, primarily developed by companies in the hemodialysis field, utilize ultra-low flow systems that are unable to remove sufficient amounts of carbon dioxide from the patient’s blood. Therefore, it is crucial to develop an ECCO2R system specifically designed for COPD patients.

LifeShield's ECCO2R system is specifically designed to remove high concentrations of carbon dioxide retained in the blood of COPD patients. It does not operate under the high flow of an ECMO system, nor at the extremely low flow of traditional ECCO2R devices, but rather finds a balance point.This ECCO2R product can not only alleviate symptoms in COPD patients in the short term but also has the potential to completely alter the course of the disease. A registration application will be submitted soon.

Compared with Germany's Maquet PLS extracorporeal circulation kit, a product known as the "industry gold standard," the LifeShield ECMO oxygenator adopts a domestically首创 "layered membrane" design and further optimizes the flow field design. The transmembrane pressure difference of the oxygenator is only 38mmHg (5L), reducing blood cell damage while offering higher gas exchange and heat exchange efficiency. At the same time, LifeShield effectively reduces the size of the blood pump, achieving a smaller priming volume, enhancing pump head stability, and improving hemolysis indicators.

At the beginning of this year,LifeShield's ECMO system has successfully completed the registered animal trials. All trial sheep reached the 16-day clinical endpoint smoothly under relevant V-V and V-A modes, achieving a 100% survival rate.。

Since the beginning of this year, three domestically produced ECMO systems have been granted emergency approval by the National Medical Products Administration. However, Dr. Tim Kaufmann is not in a rush. "Firstly, China's ECMO market is developing rapidly and still has significant gaps to fill; secondly, clinicians will use the best products to save critically ill patients, which means we must focus not only on speed but also on product performance standards, such as patient safety and clinical outcomes." Currently, LifeShield’s ECMO product has entered the clinical trial stage, and the market will soon learn about the performance and safety of LifeShield's ECMO product, as well as comparative data against similar products.

High-performance products are always the "key" for enterprises to open the door to clinical applications. In China's ECMO market,Medtronic was the first company to introduce and clinically apply this therapy, but German Maquet achieved late-mover advantage with high-performance products. A key factor lies in its unique stacked-membrane oxygenator design, which enables an effective usage duration of 14 days.To date, Maquet has maintained its leading position in the global ECMO market.

With the growth of emergency medical needs in China, the national level is also promoting the construction of ICUs and the allocation of related emergency equipment. HoweverThe price of imported ECMO products is relatively high., patients have limited payment ability, and in ChinaShortage of Medical Resources，The operation of ECMO requires the collaboration of multiple departments, and these two factors limit the popularization of ECMO therapy.

In response to the pain points in clinical practice and the market,LifeShield provides a high-performance ECMO system superior to similar products and reduces production costs through optimized design and manufacturing processes.At the same time,The company will collaborate with multiple hospitals in China to increase investment in clinical doctor training and patient education, helping to establish more ECMO centers and further promoting the普及 of ECMO therapy.。

LifeShield has built a bridge between China and Germany.The two subsidiaries, Germany's enmodes and LifeShield Medical, develop synergistically, forming a powerful combination of "German engineering technology" and "Chinese spirit."Dr. Tim Kaufmann proposed: "German engineers emphasize precision in device development, aiming to provide the best solutions; whereas in China, we have learned the spirit of rapid execution and relentless progress. Through the collaboration between Chinese and German teams, we are not only continuously updating and iterating in technology and products but also gradually integrating culturally."

In its development process, LifeShield has also built its own "circle of friends," collaborating with many partners from clinical, research, and industrial fields both in China and internationally to jointly promote the advancement of life support device technologies.

With the aggravation of population aging and the catalysis of the COVID-19 pandemic, the clinical demand for life support in China has grown rapidly. However, most companies are small in scale, and the industry concentration is relatively low. In the high-end equipment and device fields, imported products still lead. Life support is a market with high difficulty and high entry barriers, where industry giants have withstood the test of time. Dr. Tim Kaufmann also hopes that Lifeshield Medical will stand out in an increasingly competitive track with world-class products and a complete industrial chain.

In the future,LifeShield will continue to deepen its focus on the life support field, advance the clinical trials and approvals of existing products, and has already begun researching several innovative products, including the next-generation pVAD and artificial lung.In line with the trend of globalization,The company will also expand into a larger international market on the basis of establishing a strong foundation in the Chinese market.. Unlike other Chinese companies going global, LifeShield has branches in both China and Germany, and its team members have international backgrounds, giving them localized advantages in both China and Europe.

After going through the extraordinary years, when asked about the most impressive events during the development process, Dr. Tim Kaufmann replied: "I remember countless moments of breakthroughs, innovations, collaborations, and mutual care that our team has experienced together. With the same sense of responsibility and mission, we feel honored and proud to have walked this journey together."